产品上市协议（PLAs）：实现魁北克省药品政策目标的新工具？
Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives?
作者信息
Bourassa Forcier Mélanie, Noël François
机构信息
Professor and Director, Health Law and Policy Programmes, Professor, Faculty of Law, University of Sherbrooke, Sherbrooke, QC.
出版信息
Healthc Policy. 2013 Aug;9(1):65-75.
Product listing agreements (PLAs) with pharmaceutical manufacturers are increasingly viewed as an innovative and useful tool in the effort to control drug expenditures. To date, Quebec is the only province that has been reluctant to enter into such agreements, arguing that their confidential nature may lead to a disparity in coverage between individuals covered by the public plan and those covered by private insurance. While PLAs may, in fact, present such a risk, in this paper we will argue that when used correctly, these agreements are actually tools that could help attain all four of the objectives set out in Quebec's policy on medications, namely: (a) improved access to drugs, (b) fair and reasonable drug pricing, (c) optimal drug use and (d) maintaining a dynamic biopharmaceutical industry in Quebec.
与制药商签订的产品上市协议（PLA）越来越被视为控制药品支出的一种创新且有用的工具。迄今为止，魁北克是唯一不愿签订此类协议的省份，理由是其保密性质可能导致公共计划覆盖人群与私人保险覆盖人群之间在医保覆盖范围上出现差异。虽然产品上市协议实际上可能存在这样的风险，但在本文中我们将论证，若使用得当，这些协议实际上能够助力实现魁北克药品政策所设定的全部四个目标，即：（a）改善药品可及性，（b）实现公平合理的药品定价，（c）优化药品使用，以及（d）维持魁北克充满活力的生物制药产业。
Zotero 插件